DK3512857T3 - Spiro-bicykliske inhibitorer af menin-mll-interaktion - Google Patents
Spiro-bicykliske inhibitorer af menin-mll-interaktion Download PDFInfo
- Publication number
- DK3512857T3 DK3512857T3 DK17768428.9T DK17768428T DK3512857T3 DK 3512857 T3 DK3512857 T3 DK 3512857T3 DK 17768428 T DK17768428 T DK 17768428T DK 3512857 T3 DK3512857 T3 DK 3512857T3
- Authority
- DK
- Denmark
- Prior art keywords
- menin
- spiro
- mll interaction
- bicyclic inhibitors
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394295P | 2016-09-14 | 2016-09-14 | |
EP16192431 | 2016-10-05 | ||
PCT/EP2017/073004 WO2018050686A1 (en) | 2016-09-14 | 2017-09-13 | Spiro bicyclic inhibitors of menin-mll interaction |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3512857T3 true DK3512857T3 (da) | 2021-05-10 |
Family
ID=59895299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17768428.9T DK3512857T3 (da) | 2016-09-14 | 2017-09-13 | Spiro-bicykliske inhibitorer af menin-mll-interaktion |
Country Status (15)
Country | Link |
---|---|
US (1) | US11220517B2 (da) |
EP (1) | EP3512857B1 (da) |
JP (1) | JP6975791B2 (da) |
KR (1) | KR102493644B1 (da) |
CN (1) | CN109689663B (da) |
AU (1) | AU2017326487B2 (da) |
BR (1) | BR112019004691A2 (da) |
DK (1) | DK3512857T3 (da) |
ES (1) | ES2872003T3 (da) |
HR (1) | HRP20210514T1 (da) |
HU (1) | HUE053907T2 (da) |
IL (1) | IL265233B (da) |
LT (1) | LT3512857T (da) |
MX (1) | MX2019002962A (da) |
SI (1) | SI3512857T1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
US10611778B2 (en) * | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
CA3044739A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
CN112812584A (zh) * | 2019-11-16 | 2021-05-18 | 复旦大学 | 一种含氮杂环丁烷螺环结构的荧光染料及其制备方法和应用 |
TW202138367A (zh) * | 2019-12-19 | 2021-10-16 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
CN114478568A (zh) * | 2020-10-27 | 2022-05-13 | 苏州优理生物医药科技有限公司 | 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用 |
CN114516873A (zh) * | 2020-11-18 | 2022-05-20 | 苏州优理生物医药科技有限公司 | 一种螺环类化合物、包含其药物组合物及其应用 |
CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
WO2023244870A1 (en) * | 2022-06-17 | 2023-12-21 | INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | Compositions and methods for control of transient site-specific copy gains, genomic insertions, and rearrangements associated with mixed lineage leukemia |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
NZ534801A (en) | 2002-02-19 | 2006-04-28 | Cv Therapeutics Inc | Partial and full agonists of A1 adenosine receptors |
US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
JP4660199B2 (ja) | 2002-12-23 | 2011-03-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換1−ピペリジン−4−イル−4−アゼチジン−3−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
WO2005110410A2 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
US20080102068A1 (en) | 2005-01-19 | 2008-05-01 | Coleman Paul J | Mitotic Kinesin Inhibitors |
GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
US8831510B2 (en) | 2008-10-06 | 2014-09-09 | Nec Corporation | Wireless communication device, wireless communication system, controlling method for wireless communication device, and recording medium |
JP2011026305A (ja) | 2009-06-24 | 2011-02-10 | Daiichi Sankyo Co Ltd | イミダゾールカルボニル化合物を含有する医薬組成物 |
EP2467367B1 (de) * | 2009-08-20 | 2014-04-09 | Bayer CropScience AG | 3-triazolylphenyl-substituierte sulfid-derivate als akarizide und insektizide |
JP5792171B2 (ja) | 2009-09-04 | 2015-10-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 白血病を治療するための組成物および方法 |
US9586961B2 (en) * | 2010-07-09 | 2017-03-07 | Leo Pharma A/S | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
RU2013130253A (ru) | 2010-12-03 | 2015-01-10 | Эпизайм, Инк. | 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения |
JP5242865B1 (ja) | 2011-08-01 | 2013-07-24 | オリンパスメディカルシステムズ株式会社 | 挿入部形状推定装置 |
WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
CN103664991B (zh) | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
CN104918939B (zh) * | 2012-11-16 | 2018-08-28 | 默沙东公司 | 人磷脂酰肌醇3-激酶δ的嘌呤抑制剂 |
US8906900B2 (en) | 2012-12-21 | 2014-12-09 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US9505781B2 (en) * | 2013-03-13 | 2016-11-29 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
EP3139902A2 (en) * | 2014-05-06 | 2017-03-15 | The Procter & Gamble Company | Fragrance compositions |
WO2015191701A1 (en) | 2014-06-10 | 2015-12-17 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
WO2016081732A1 (en) | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
TN2017000357A1 (en) | 2015-02-24 | 2019-01-16 | Pfizer | Substituted nucleoside derivatives useful as anticancer agents |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
MX2018007703A (es) | 2015-12-22 | 2018-11-09 | Vitae Pharmaceuticals Inc | Inhibidores de la interaccion de menina-linaje leucemico mixto. |
BR112018068702A2 (pt) | 2016-03-16 | 2019-01-15 | Kura Oncology Inc | inibidores bicíclicos em ponte de menin-mll e métodos de uso |
EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
BR122024002146A2 (pt) | 2016-06-10 | 2024-03-05 | Vitae Pharmaceuticals, Inc. | Compostos inibidores da interação de menina-llm e forma cristalina destes |
WO2018024602A1 (en) * | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
CN109689815B (zh) | 2016-09-06 | 2022-06-14 | 三键有限公司 | 热固化型导电性胶粘剂 |
CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
US10611778B2 (en) | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
EP4230627A3 (en) | 2016-09-16 | 2023-11-15 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
-
2017
- 2017-09-13 AU AU2017326487A patent/AU2017326487B2/en active Active
- 2017-09-13 LT LTEP17768428.9T patent/LT3512857T/lt unknown
- 2017-09-13 MX MX2019002962A patent/MX2019002962A/es unknown
- 2017-09-13 SI SI201730700T patent/SI3512857T1/sl unknown
- 2017-09-13 DK DK17768428.9T patent/DK3512857T3/da active
- 2017-09-13 JP JP2019535974A patent/JP6975791B2/ja active Active
- 2017-09-13 US US16/331,606 patent/US11220517B2/en active Active
- 2017-09-13 CN CN201780056188.3A patent/CN109689663B/zh active Active
- 2017-09-13 ES ES17768428T patent/ES2872003T3/es active Active
- 2017-09-13 BR BR112019004691A patent/BR112019004691A2/pt unknown
- 2017-09-13 KR KR1020197008627A patent/KR102493644B1/ko active IP Right Grant
- 2017-09-13 EP EP17768428.9A patent/EP3512857B1/en active Active
- 2017-09-13 HU HUE17768428A patent/HUE053907T2/hu unknown
-
2019
- 2019-03-07 IL IL265233A patent/IL265233B/en active IP Right Grant
-
2021
- 2021-03-30 HR HRP20210514TT patent/HRP20210514T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HUE053907T2 (hu) | 2021-07-28 |
LT3512857T (lt) | 2021-04-12 |
AU2017326487B2 (en) | 2021-08-05 |
EP3512857A1 (en) | 2019-07-24 |
BR112019004691A2 (pt) | 2019-06-25 |
JP2019532100A (ja) | 2019-11-07 |
KR20190045242A (ko) | 2019-05-02 |
ES2872003T3 (es) | 2021-11-02 |
MX2019002962A (es) | 2019-07-04 |
US11220517B2 (en) | 2022-01-11 |
KR102493644B1 (ko) | 2023-01-30 |
JP6975791B2 (ja) | 2021-12-01 |
IL265233B (en) | 2021-06-30 |
IL265233A (en) | 2019-05-30 |
AU2017326487A1 (en) | 2019-02-28 |
CN109689663A (zh) | 2019-04-26 |
CN109689663B (zh) | 2023-04-14 |
SI3512857T1 (sl) | 2021-07-30 |
HRP20210514T1 (hr) | 2021-05-14 |
US20190211036A1 (en) | 2019-07-11 |
EP3512857B1 (en) | 2021-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
DK3371171T3 (da) | Inhibitorer af RET | |
DK3377059T3 (da) | Hæmmere af cxcr2 | |
DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
DK3442972T3 (da) | Bromdomænehæmmere | |
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
DK3554240T3 (da) | Kombinationer af aktive forbindelser | |
DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
DK3244891T3 (da) | Forbindelser til forbedring af mrna-splejsning | |
DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
DK3180331T3 (da) | Polymorfer af selinexor | |
DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
DK3457851T3 (da) | Derivater af sobetirom | |
DK3261726T3 (da) | Sammensætning til behandling af acne | |
DK3341379T3 (da) | EZH2-hæmmere | |
DK3307267T3 (da) | Behandling af multipel sklerose |